logo-loader
viewReNeuron Group PLC

ReNeuron treatment for degenerative eye condition “meaningful effect” for all points measured up to 18 months

Chief executive Olav Hellebø said: “The persistence of the observed clinical benefit is particularly encouraging”

ReNeuron Group PLC -

ReNeuron Group PLC (LOM:RENE) said its treatment for a hereditary form of progressive blindness has been shown to have a “meaningful effect” for all points measured up to 18 months.

Its study of its human retinal progenitor cell (hRPC) therapy showed the single retinitis pigmentosa patient dosed a year and a half ago was able to read 16 more letters from a standard chart with the treated eye than with the untreated eye.

Chief executive Olav Hellebø said: “The persistence of the observed clinical benefit is particularly encouraging.”

The update built on the data from February which assessed the efficacy of the treatment to 12 months.

Earlier this month ReNeuron said both the US and UK drug regulators had approved an expansion of the company’s phase IIa clinical study to treat a further nine patients at higher dose levels with work set to begin shortly.

It said it expects to release updates from the expanded trial during the next 12 months, and, crucially, hopes to seek approval for a pivotal study in the second half of next year.

Quick facts: ReNeuron Group PLC

Price: 142.5 GBX

LSE:RENE
Market: LSE
Market Cap: £45.36 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 posts early losses sparked by rising US coronavirus...

Headlines from the Proactive UK newsroom. FTSE100 posted early losses sparked by rising US coronavirus infections and China’s trade row with the US. The blue-chip index shed 10 points to 6,112. Royal Mail PLC (LON:RMG) is to axe 2,000 jobs or more than 20% of its managerial staff as part...

2 weeks, 2 days ago

2 min read